Silicon Therapeutics (“SITX”) is a privately-held, physics-driven integrated drug discovery company in the preclinical IND stage targeting innate immunity to start, but with the capability to move into many other franchise opportunities. The Company’s initial pipeline is focused on modulation of the innate immune system to “light the spark” within immunologically cold tumors by using its physics-enabled drug discovery engine for the design of small molecule therapeutics and the lead program is in late stage preclinical studies. SITX’s discovery efforts as well as physics-based platform are all completely in-house, with a full wet lab as well as a team of over 25 experienced R&D professionals spanning biology, biochemistry, chemistry, biophysics (NMR + X-ray) & preclinical sciences. SITX’s engine leverages quantum mechanics and molecular dynamics, which are deployed on its own internal super computer composed of over 400 GPU’s and FPGA’s and allows SITX to accurately simulate the physical motion and properties of biological targets at an atomistic level resolution. The platform is completely proprietary to SITX and was built from the ground up with the purpose of addressing difficult targets and using simulations to break through bottlenecks that has plagued traditional drug discovery approaches on such targets. It is currently the ONLY company which owns the entire spectrum of physics-driven drug discovery from chip-to-clinic with a team of over 40 individuals in Boston.
The Company’s initial focus in on innate immunity and its pipeline is currently composed of one project entering into IND-enabling studies, another one entering hit-to-lead and two more ramping up. It’s unique advantage in designing small molecules using all atom simulations has allowed it to advance a systemically available small molecule STING agonist into a preclinical development. The program is ramping up for IND enabling studies entry to the clinic in 2020. This differentiated product can be administered systemically via an IV dose and has single agent effects in early mouse efficacy studies using PD1 resistant tumor models and is a “rule-of-5” compliant small molecule. Beyond this one program, the Company is also advancing an ADAR inhibitor which can be considered an innate immune check-point as well as a multitude of targets that explore Innate Immunity’s role in cancer biology.
Silicon Therapeutics is seeking an enthusiastic, motivated and capable individual with expertise in enzymology, biochemistry, assay development and compound screening. Core responsibilities include biochemical assay development, small molecule hit-ID screening and routine testing of compounds in a variety of assays. This is an exciting role for a scientist who is looking to contribute to the discovery and development of cancer therapies. The successful candidate will work as part of a collaborative team of scientists with expertise in protein production and biophysics supporting hit-ID, hit-to-lead, and lead-ID phases of our innate immuno-oncology drug discovery programs and will have the opportunity to mentor and lead more junior scientists.
- Core responsibilities: design and develop in vitro biochemical assays for compound library screening and routine small molecule testing.
- Additional responsibilities could include testing of small molecules in cell-based assays.
- In collaboration with group members, design protein constructs for use in biochemical assays.
- Work as part of a cross-functional project team to provide high-impact results.
- Carefully document research workflows, data and protocols using an electronic laboratory notebook.
- Capture experimental results in database.
- Organize and present data to group members and project team members.
- Mentor and lead more junior scientists within the group.
Required Skills & Qualifications
- Ph.D. with 4+ years (Senior Investigator) or 8+ years (Principal Investigator) of industry experience with a degree in enzymology, biochemistry or related discipline.
- Expertise in in vitro biochemical assay design and development in multiple enzyme formats (FRET, FP, fluorometric, colorimetric, ELISA, etc.), medium-throughput compound library screening, and testing of small molecules for determining inhibition/binding.
- Application of mathematical binding/inhibition models to determine small molecule mechanism of action (cooperativity, competitive/non-competitive, etc).
- Hands-on experience in cell-based assay design and development and testing of small molecules for determining inhibition/cytotoxicity/plasma protein binding.
- Proficient in relevant programs for data analysis and visualization.
- Demonstrated ability to troubleshoot and optimize experiments.
- Demonstrated ability to lead and mentor others.
- Excellent communication skills.
- Experience with proteins that bind to or modify oligonucleotides is a plus.